Over 15M people take GLP-1 drugs in America and 54% agree on same issue
15 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Over 15M people take GLP-1 drugs in America and 54% agree on same issue" is generating significant coverage in the Health category, with 17 articles from 15 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Hackensack Meridian Health, Yahoo Health, Mexico Business News and Nutrition Insight. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 32d ago.
Quick answers
Why is "Over 15M people take GLP-1 drugs in America and 54% agree on same issue" trending?
Because 15 independent news sources published 17 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (17)
- Beyond the Scale: 4 Proven Health Benefits of GLP-1s Hackensack Meridian Health · 41d ago
- Yes, GLP-1s Are Changing What Food People Buy Yahoo Health · 41d ago
- GLP-1 Drugs Push Food Industry to Rethink Portions, Products Mexico Business News · 41d ago
- GLP-1 users reshape nutrition product development, say ADM, Cargill & Synergy Flavours Nutrition Insight · 41d ago
- As GLP-1 Drugs Change How People Eat, Drugmakers Collect and Snack Makers Feel the Squeeze The Motley Fool · 41d ago
- One year of weight-loss drugs in India: What happened to the ‘Mounjaro brides’? The Indian Express · 41d ago
- How Are Glp-1s Reshaping the Conversation Around Weight Loss? The Good Men Project · 41d ago
- Johns Hopkins research finds broad weight-loss benefits from GLP-1 drugs ConsumerAffairs · 41d ago
- glp-1 weight loss drug news august 1 2025 Olhar Digital · 41d ago
- Philly eating disorder treatment providers, people in recovery on how they navigate GLP-1 weight loss culture shift WHYY · 41d ago
- fda approved peptides for weight loss Olhar Digital · 41d ago
- glp1 weight loss drug marketplace florida changes 2025 BusinessWorld Online · 41d ago
- glp 1 agonist and weight loss Olhar Digital · 41d ago
- I’m a weight loss expert — this is why GLP-1s don’t work for everyone The Independent · 41d ago
- GLP-1 Drugs Market to Reach USD 132.79 Billion by 2035 as GlobeNewswire · 41d ago
- 5 surprising lessons about GLP-1s, from the scientists who study them BBC Science Focus Magazine · 41d ago
- Over 15M people take GLP-1 drugs in America and 54% agree on same issue The Mirror US · 41d ago
Topics
Related trends
GLP-1 poison calls surge in Georgia as experts warn about unapproved weight-loss drugs - WSB-TV
Georgia poison centers report a surge in calls linked to GLP-1 weight-loss drugs as experts flag risks from unapproved versions.
Should you take GLP-1s during pregnancy? What some doctors say.
New research on GLP-1 drugs during pregnancy sparks urgent debate among doctors and patients.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Taking GLP-1s forever? 5 strategies to keep weight off if you stop
New Cleveland Clinic research maps five evidence-based exit strategies for patients discontinuing GLP-1 weight-loss drugs, a question facing millions as supply and cost pressures mount.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.